Sanara Medtech Inc（SMTI）資訊與事件SMTISanara Medtech Inc

H.C. Wainwright Downgrades Sanara MedTech to Neutral, Price Target Cut to $35

H.C. Wainwright downgraded Sanara MedTech to Neutral from Buy with a price target of $35, down from $36, after the company entered into a merger agreement under which MiMedx will acquire it in a cash and stock transaction valued at $35 per share.

MiMedx to Acquire Sanara MedTech for $35 per Share

MiMedx Group (MDXG) and Sanara MedTech (SMTI) announced that they have entered into a definitive merger agreement under which MiMedx will acquire all of the outstanding shares of Sanara in a cash and stock transaction valued at $35 per Sanara share with a total enterprise value of approximately $350M. Under the terms of the agreement, Sanara shareholders will receive $33 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara common stock they own, which represents a value of $2 per share, calculated based on the average closing price of MiMedx common stock of $4.22 for the last five consecutive trading days through and including July 28. The merger consideration represents a premium of 46% to Sanara's 30-day volume weighted average share price as of July 28. MiMedx expects to finance the cash portion of the transaction through a combination of cash on hand and a new, committed debt financing in the form of a $300M term loan, which has been secured with Hayfin Capital Management. In connection with the execution and delivery of definitive documentation with respect to the debt financing by Hayfin, MiMedx's existing credit agreement will be terminated and all amounts outstanding will be repaid in full. The transaction is expected to nearly double MiMedx's surgical revenue and is expected to be immediately accretive to MiMedx's revenue growth rate, gross margin and adjusted EBITDA margin. The company anticipates over $20M in run-rate cost synergies. On a combined basis, 2027 total revenue is expected to be well in excess of $400M with an adjusted EBITDA margin expected to be over 20%. The transaction has been unanimously approved by the board of directors of both companies and is expected to close by the end of the year, subject to approval by Sanara shareholders, the receipt of required regulatory approvals and other customary closing conditions. Centerview Partners is serving as exclusive financial advisor to MiMedx; Greenberg Traurig is serving as legal advisor. Truist Securities is serving as exclusive financial advisor to Sanara; Alston & Bird is serving as legal advisor. Joseph Capper, MiMedx CEO, said, "We are thrilled to announce the planned combination with Sanara MedTech and look forward to welcoming their team to the MIMEDX family in the near future. Over the last several years, MIMEDX has demonstrated the ability to drive strong, double-digit growth in surgical end markets. With Sanara, we will accelerate this effort and meaningfully expand our reach across several subspecialties. On a combined basis, 2027 total revenue is expected to be well in excess of $400 million with an adjusted EBITDA margin expected to be over 20%."

Sanara MedTech Q1 Revenue Up 19%, Shares Rise 22%

Last night, the company also reported Q1 revenue $27.8M vs. $23.4M last year. Seth Yon, CEO, commented, "The first quarter of 2026 is the first full quarter in which the Company was entirely focused on the surgical market, and the results reflected strong execution. We delivered net revenue growth of 19% and gross margin improvement, and achieved GAAP net profitability, a reflection of the strength of our sharpened focus and enhanced financial model. We're particularly encouraged by these results given that the first quarter is historically our slowest sales period of the year and was also impacted by a three-day shipping interruption in January due to a weather-related shut down. During the end of 2025 and continuing into 2026, we began strengthening our sales team in an effort to support enhanced net revenue growth and our heightened focus on the surgical setting, expanding the sales team to reach a total of 43 reps. Additionally, we experienced meaningful growth in our surgeon users in the first quarter of 2026 as compared to the first quarter of 2025, and, as of quarter end, our products were contracted or approved to be sold in over 4,000 hospitals and ambulatory surgery centers throughout the United States, our products were sold in over 1,400 facilities throughout the United States, and we had agreements with more than 450 distributors. Looking ahead, we believe we are well positioned with our strengthened sales team and refined, pure play focus on the surgical operating setting to drive enhanced results. From a capital allocation perspective, this means tightening our scope and strategically investing in R&D to grow our pipeline and introduce new products to the market. With our visibility today, we remain confident in our full-year guidance of 13% to 17% net revenue growth." Shares of Sanara MedTech are up 22% in pre-market at $22.04.